Market Pulse · Daily Scan
Daily Market Pulse
Jul 22, 2026 · sentiment/flow window ≈ 48h · Backdated run. Track A reflects the Wed 2026-07-22 regular-session close and the 48h window Mon 07-20 -> Wed 07-22. Any figure sourced after 2026-07-22 is explicitly marked with a post_run_date_vintage flag or an inline '(quote as of ...)' stamp. Post-run-date PRICE REACTIONS (07-23 / 07-24) were deliberately excluded from all scoring so the run is not contaminated by look-ahead; GOOGL/TSLA/IBM/NOW Q2 results are included only because they were released AMC on 07-22 itself.
Pre-marketnot publishedPost-market
TLDR;
Choppy, narrowing tape into the single most important AI-capex earnings night of the quarter. Monday 07-20 was a narrow, negative-breadth risk-off session (only 207 S&P constituents advanced) on fresh US strikes on Iran and a Houthi maritime-embargo threat. Tuesday 07-21 was a broad, chip-led melt-up (Nasdaq +1.29%, SOX +5%) as strong South Korean semiconductor export data triggered a memory/storage repricing. Wednesday 07-22 gave much of it back in a defensive rotation: Energy, Materials and Utilities were the only sectors bid, Technology (XLK -1.40%) lagged, and the market de-risked into the after-the-bell prints. Alphabet, Tesla, IBM and ServiceNow all reported AMC on 07-22. Alphabet beat on every line (revenue $119.8B +24%, Cloud +82%) but raised FY26 capex to $195-205B from $180-190B; Tesla beat on revenue and deliveries (480,126, +25%) but missed badly on EPS ($0.33 vs ~$0.51) with capex up 142%. That combination - beats paired with capex raises - is the defining tension of the run, and the reason the falling list is populated by names that beat-and-raised and sold off anyway (TEL, DHR, NOC). Breadth: Deteriorating / narrow. Two-thirds of stocks fell on 07-20; 07-21 saw the healthiest breadth in two weeks (only 3 of 11 sectors lower); 07-22 reverted to narrow with leadership confined to Energy/Materials/Utilities while Tech and Communication Services led lower and small caps underperformed (Russell 2000 -0.92% vs S&P -0.14%). Precise NYSE/Nasdaq advance-decline counts for 07-22 are UNVERIFIED..A · Daily Pulse
What moved — and why
▲ Rising — dailycomposite
| # | Ticker | Move | Driver | Score |
|---|---|---|---|---|
| 1 | INTC | +8.6% | Rode the 07-21 chip rally (SOX +5%) into a 07-23 AMC earnings print with the single richest event premium in the window. Weekly IV roughly 2x the top of its own annual range is the cleanest verified options signal of the run; the market was pricing a ~13% move. Catalyst score is proximity-driven, not conviction-driven. | 88 |
| 2 | SMCI | +19.84% | PUMP RISK - reported prominently, not suppressed. The +19.84% close (+28% over two sessions) rests on a company pre-announcement of a record ~$60B backlog and a Q4 gross-margin guide up to 15-17% from 8.2-8.4%. But: the backlog figure is self-reported and unaudited, the revenue outlook in the same release was SOFT, the primary press release was not retrievable (ir.supermicro.com returns 404) so the $60B rests entirely on secondary summaries, and this is a low-priced, high-retail-attention AI-hardware name. Two of five pump criteria confirmed (Tier-3 mention spike, heavy short-dated call-side premium); the vertical move DOES have a Tier-1-class catalyst, which is the mitigating factor. Catalyst subscore is discounted to 78 for the unverifiable primary source. pump risk | 87 |
| 3 | MU | +12.17% | Epicentre of the 07-21 memory melt-up on strong South Korean semiconductor export data. Highest credibility-weighted sentiment velocity in the window: top-2 on both r/wallstreetbets and StockTwits AND carrying a genuine Tier-1-quoted sell-side catalyst (BofA's 8th-consecutive-beat note, HBM TAM to $246B by 2030; UBS modelling >40% share repurchase and >$400B FCF through 2028). Counterweight the options subscore: the flow was put-selling, which monetises elevated IV rather than expressing upside conviction. Track B research separately flags memory as LATE-CYCLE (DRAM contract pricing decelerating +90-95% -> +58-63% -> +13-18% QoQ; customer inventories 7-9 weeks vs an 8-week warning line) - this name is a strong Track A signal and explicitly NOT on the Track B upside list. ↔ deep-dive | 82 |
| 4 | SNDK | +14.27% | PUMP RISK (medium) - flagged, not suppressed. Largest social mention gainer in the window with $40.4M of call-side premium and a vertical two-day move (+6% on 07-20, +14.27% on 07-21), attributed by the source explicitly to SECTOR sentiment with NO company-specific catalyst - which is why the catalyst subscore is 45. Mitigating: the underlying memory-pricing thesis is Tier-1 supported via the MU sell-side notes, the market cap is large, and the concurrent $33M of put-side premium suggests genuine hedging rather than pure retail chase. Context worth holding: this name is reported up ~3,240% over 52 weeks - the single most extended chart in the complex. pump risk | 80 |
| 5 | AMD | +8% | Two-day move carried by a Tier-1 catalyst - an expanded Microsoft Azure partnership bringing Helios Rackscale into Azure - layered on the broad 07-21 semiconductor bid. A separate reported AMD/Anthropic $5B + 2GW MI450 arrangement was single-sourced and is treated as UNVERIFIED, so it is excluded from the catalyst subscore. | 67 |
| 6 | CBRS | +16% | Second-largest verified single-day gain in the window on a CrowdStrike partnership - Falcon AI Detection & Response built on Cerebras inference. Catalyst is Tier-2 reported rather than confirmed from either company's IR, so the catalyst subscore is capped at 58 and the exact close is UNVERIFIED. Recent-IPO float dynamics are a live but unquantified consideration. | 66 |
| 7 | WDC | +12.5% | Pure participation in the 07-21 memory/storage repricing. No company-specific catalyst was found, which caps the catalyst subscore at 40 - this is beta to the MU/SNDK factor, and it is here on momentum alone. | 63 |
| 8 | DELL | +9.32% | A +9.32% move in a ~$148B company with ZERO company-specific news - pure sympathy to SMCI's pre-announcement. That is the sentiment-contagion marker of the window and the reason the catalyst subscore is 30. Notable that the options chain was leaning PUT-heavy into the rally, i.e. someone was fading it. | 63 |
| 9 | WAB | +10.04% | The highest-quality Tier-1 catalyst in the rising list and the counter-example to the week's 'beat-and-raise sold off' pattern. Q2 adjusted EPS $2.76 (a $0.15 beat), revenue $3.18B +17.3%, FY guidance raised - PLUS a Vale contract and a $1.2B Union Pacific award disclosed the same day. Low sentiment velocity is a feature here, not a defect: no retail crowding to unwind. | 62 |
| 10 | MMM | +7.32% | Included specifically to break the semis concentration with a defensible non-tech name. Q2 adjusted EPS $2.40 vs ~$2.25, organic growth +5.4% (best in five years), FY EPS guidance raised to $8.80-8.95. The +7.32% move meaningfully exceeded the +/-5.60% the options market had priced - a genuine surprise, not a repricing of known information. | 58 |
▼ Falling — dailycomposite
| # | Ticker | Move | Driver | Score |
|---|---|---|---|---|
| 1 | GEV | −8.69% | The cleanest expression of the window's organizing theme. Revenue beat and FY guidance was RAISED, but Q2 EPS came in at $2.47 against $3.04-3.13 consensus - a wind-segment drag - and the stock had already run ~80% in H1. When a stock is priced for perfection, a raised full-year guide does not rescue a missed quarter. Options had pre-positioned for size (weekly IV ~58% above the top of its annual range) without directional conviction. | 76 |
| 2 | DHR | −10.99% | Beat both lines AND raised FY EPS - and fell 11%. The trigger was ~$100M of bioprocessing revenue pushed into 2027 plus a 160bp Diagnostics margin decline. The move exceeded the options-implied +/-7.26% by half again. Honesty flag: DHR rebounded +7.46% on 07-23, one day after this run - so this print substantially round-tripped. Momentum subscore is high on magnitude, but the durability of the signal was poor. | 75 |
| 3 | MSCI | −10.14% | The top/bottom-line miss was slight; the -10% came from 2026 opex guidance raised to $1.535-1.575B on First Street integration, compounded by AI-disruption fear attaching to index and analytics franchises. This is the same terminal-value anxiety that repriced app-layer software earlier in 2026 arriving at a data/index business - which makes it a structural read-through, not just a bad quarter. | 69 |
| 4 | RDDT | −8.32% | Fell on a Wall Street Journal report that Reddit may restrict Google's AI access or demand higher fees as the ~$60M/yr licensing deal nears expiry. Important separation of fact from inference: the REPORT is Tier-2 media, not a company disclosure or filing - neither party confirmed it. Catalyst subscore capped at 60 accordingly. What the market appears to be pricing is not the licensing revenue itself but the fragility of data-licensing as a revenue line. | 67 |
| 5 | PLTR | −6.1% | No single confirmed catalyst - this is de-risking ahead of the GOOGL/TSLA prints in the most crowded retail long in the market, which is exactly why the catalyst subscore is 25 and the sentiment-velocity subscore is 88. Adjacent Tier-2 items in the window that may have contributed but were not confirmed as the driver: UK NHS contract under regulatory scrutiny (07-22) and a challenged London police contract (07-09). I INFER positioning unwind rather than news; I cannot demonstrate it. retail-heavyunverified | 64 |
| 6 | WBD | −3.76% | Highest-quality Tier-1 catalyst in the falling list: a federal judge issued a temporary restraining order pausing the $110B Paramount Skydance transaction for at least 14 days, with a hearing set for 08-03. The stock trades ~20% below the $31/share cash offer - the spread IS the market's probability estimate of the deal breaking. Modest percentage move, high information content. | 63 |
| 7 | HAL | −5.47% | Double beat (EPS $0.55, revenue $5.71B) and still -5.47%, because Middle East/Asia revenue fell 10.7% YoY on Kuwait/Iraq/Qatar conflict disruption. This is the Track A instance of a structural point developed independently in Track B: oilfield services LOSE in both oil regimes - war lifts the crude price but halts the drilling they are paid for, and peace lowers the price and cuts operator budgets. WTI was up 3.3% on 07-22 while HAL was down. | 62 |
| 8 | ISRG | −2.68% | Smallest move on the falling list and the most durable information in it. The FDA granted marketing authorization to Johnson & Johnson's Ottava robotic surgical platform - the first credible US rival to da Vinci in soft-tissue robotics. That is a Tier-1 regulatory fact that permanently changes a competitive position, not a quarterly datapoint, and it is the reason the catalyst subscore is 92 against a momentum subscore of 52. ISRG was already reported down ~35% YTD into this. JNJ rose 2.00% the same session on the other side of the same event. | 59 |
| 9 | RYAAY | −5.85% | Tier-1 catalyst with unusual severity: FQ1 net profit fell 34% to EUR 538M, fares -6%, and management WITHHELD full-year guidance citing 'zero H2 visibility', with fuel at $151/bbl and 20% unhedged. A guidance withdrawal is a stronger signal than a miss - it says management cannot model its own year. This is the cleanest single-name transmission of the oil shock into the consumer-cyclical complex. | 57 |
| 10 | TEL | −4.18% | The purest 'beat-and-raise sold off' instance of the window. Record orders of $5.7B (+27%) and guidance above consensus were entirely overridden by a $1.4B Astrodyne TDI acquisition announced alongside. Classic acquirer de-rating: in a regime where the market has begun punishing capital deployment as cost rather than rewarding it as growth, an acquisition announced on results day is a liability. Note the intraday print circulating at -6.9%/-7% is wrong; the closing basis is -4.18%. | 54 |
B · One-Year Conviction
Asymmetric 12-month skew
Free sources only. Valuation multiples and market caps are Tier-2 aggregator data (stockanalysis.com, sourcing S&P Global Market Intelligence / TipRanks) - NOT SEC-verified - and most quotes carry a 2026-07-24 to 2026-07-26 vintage, i.e. AFTER the nominal run date. Post-run-date PRICE REACTIONS were excluded from scoring. FY2027 consensus is paywalled for many tickers; where it was unavailable, 'estimate revisions' is inferred from price-target revision direction and current-year growth rather than from an observed estimate series, and the subscore is capped accordingly. True estimate-revision history (dollar revisions over time) is not available on any free source.
▲ Upside skew — 1yrconviction
| Ticker | Thesis | Key risk | Score |
|---|---|---|---|
| TSM | The unavoidable chokepoint of the AI buildout and the cheapest way to own the cycle. Every other semiconductor name in this research - NVDA, AVGO, AMD, MRVL, CRDO, ALAB - is a TSMC customer, so it monetises the compute buildout regardless of whether merchant GPUs or custom ASICs win the architecture war. In a regime that has begun punishing capex spenders and de-rating high-multiple beneficiaries, TSM offers ~31% forward-year revenue growth at 19.05x forward earnings with $79.70B of net cash. Explicit forward-year consensus was obtainable here, which is rare in this dataset: 2026 revenue NT$5.38T (+41.4%), EPS NT$106.35 (+60.5%), 37 analysts; 2027 revenue NT$7.05T (+30.9%), EPS NT$136.05 (+27.9%). July PT raises: Barclays $625->$650 (07-16), TD Cowen $400->$440 (07-17). The persistent discount is geopolitical, not operational. | Taiwan geopolitical tail risk - unhedgeable, and the sole reason for the multiple discount; TSM bears the capex burden of the entire cycle (leading-edge plus CoWoS packaging), so a hyperscaler digestion phase hits its own capital intensity; reported 'TSMC stake sale' among June 2026 supply-chain worries - UNVERIFIED | 90 |
| GOOGL | The only megacap that is simultaneously the AI model layer, the distribution layer and the cloud layer, and the only one in this set with ACCELERATING revenue growth. The Q2 print released AMC on the run date itself delivered revenue $119.8B (+24%) with Cloud +82%; the prior quarter delivered EPS $5.11 against $2.63 consensus with Cloud +63% on a $460B backlog. 2026E revenue $489.12B (+21.4%), accelerating from +15.1% in 2025; 2026E EPS $14.26 (+31.9%). Of 64 covering analysts, ZERO rate it Sell. The capex raise disclosed on the run date is precisely the regime change described above - the market repricing capex as cost - and that repricing is what creates the entry rather than invalidating the thesis. | FY26 capex of $195-205B plus $811B of contracted future commitments materially compresses FCF - and the market has just demonstrated it will punish that; antitrust remedy overhang unresolved; search-query cannibalisation by AI assistants is a genuine long-term unknown that no current number resolves | 85 |
| NVDA | Carries the lowest forward multiple of any high-growth name in the AI complex (20.76x) while generating the highest free cash flow ($119.08B), having already de-rated relative to its growth while froth migrated into memory and optics. Its 52-week range ($164.07-$236.54) is the NARROWEST in the complex - roughly 44% peak-to-trough versus SNDK's reported +3,240% - meaning it is the least-crowded, most-owned-on-fundamentals name in a group where positioning is the primary risk. FY2027 consensus: revenue $393.6B, EPS $8.99, 53 analysts as of 07-22. The ~$500B NVIDIA-SK Group AI initiative locks down HBM supply - NVDA using its balance sheet to secure the one input that could constrain it. | ASIC substitution at the margin (Broadcom/Google TPU, Trainium) - the live architectural debate; hyperscaler concentration: any one of the big five cutting capex is the direct offset, and MSFT (07-29), AMZN and META are the swing events; China export restrictions remain an unquantified overhang | 84 |
| VST | The AI-power theme is fundamentally intact and broken on multiple, and that gap is the trade. Order evidence is stronger than at any point in the cycle (GE Vernova orders +88% YoY on a $176B backlog; Eaton Electrical backlog +29% with 1.1 book-to-bill; Quanta $48.5B backlog) while merchant IPPs sit 20-33% below their 52-week highs. The de-rating driver is the DISCOUNT RATE, not demand - and Vistra is where that dislocation is widest at 17.44x forward, 10.79x EV/EBITDA and a PEG of 0.38. All six Jun-Jul analyst actions maintained Buy; Wells Fargo moved its target $152 -> $259 on 07-03. FY2026E revenue $23.28B (+31.23%), EPS $8.45 (+77.55%). ERCOT + PJM merchant nuclear/gas fleet with direct hyperscaler exposure, plus the June 2026 KKR/Nvidia/Vistra 'Helix Digital Infrastructure' $10B venture. Backdrop: Morgan Stanley models US data-centre power demand at 74 GW by 2028 against ~25 GW available today. | D/E 3.55 and $19.93B of debt into a probable September hike - the most rate-exposed name on this list; merchant power spreads are unhedged commodity exposure, so a mild weather year is an earnings miss; the source statistics page is cached 2026-05-29 - multiples are approximate | 83 |
| MSFT | A SELLER of the agentic tools disrupting the rest of software, trading at the cheapest forward multiple in years (20.61x) and ~31% below its high with estimates still accelerating. Azure + Copilot + the OpenAI stake is the widest moat in software, and unlike app-layer SaaS it sits on the correct side of the seat-pricing question. FY26E revenue $329.55B (+17.0%), accelerating from +14.9%; FY26E EPS $16.77 (+23.0%). 42 Strong Buy / 13 Buy / 3 Hold of 58. ↔ deep-dive | the 07-29 capex guide is the sector's key swing factor - MSFT is NOT exempt from the capex-as-cost repricing that hit Alphabet, and it lands INSIDE the catalyst horizon of this run; sources conflict materially on MSFT's own 2026 capex - $120B+ (Futurum, Forbes) vs ~$190B (Tier-3 aggregator) - UNVERIFIED; Copilot seat monetisation is the same seat model being questioned elsewhere | 82 |
| AZN | The only large-cap pharma compounding EPS at a double-digit rate THROUGH its own IRA repricing, without needing an obesity story or a patent cliff to defend. Farxiga was in IRA Round 1 with negotiated prices effective 2026-01-01 - and AZN is still guiding to ~12% EPS growth in both 2026 and 2027. Verified forward years: 2026 revenue $63.21B (+7.62%), EPS $10.25 (+11.94%); 2027 revenue $66.79B (+5.66%), EPS $11.51 (+12.25%). JPMorgan moved $165 -> $213 on 2026-07-21 - a 29% target increase one day before the run date. Consensus PT implies the widest upside of any large-cap pharma in this research. | drug-pricing policy is now a REALISED earnings event rather than an overhang - which cuts both ways; extreme target dispersion: Deutsche $153 vs Jefferies $233, a 52% bull/bear gap; HSBC downgraded at $183 (07-13) and Morgan Stanley cut $220->$204 (07-16); ADR structure adds FX translation risk | 79 |
| MRK | Merck is pre-empting its own 2028 Keytruda cliff rather than waiting for it - systematically approving KEYTRUDA QLEX (subcutaneous) in lockstep with every new IV indication (TNBC 1L with Trodelvy 06-25; muscle-invasive bladder cancer with Padcev 07-10). Converting a franchise to a patent-protected subcutaneous formulation ahead of IV biosimilars is the entire LOE mitigation thesis, and it is executing on schedule. It separately opened a new market on 2026-07-16 when the FDA approved LIPFENDRA (enlicitide), the first and only once-daily ORAL PCSK9 inhibitor. READ THE VALUATION CAREFULLY: 2026 EPS consensus is $2.74 (-69.43%), a one-off charge year, versus 2027 EPS $9.66 (+251.83%) - roughly 13.6x 2027 earnings. Any screen ranking MRK on 2026 P/E produces a false signal. | +56% over 52 weeks against a consensus PT of $134.04 (+2.27%) - the re-rating has largely happened; the QLEX conversion rate is NOT disclosed - it is the single most important number for this thesis and it is UNVERIFIED; $43.4B net debt; MK-1167 Alzheimer's Phase 2 terminated ~07-19; source data conflict: quote page shows PT $131.70 vs forecast page $134.04, unreconciled | 78 |
| LLY | The single most important structural fact in mid-2026 healthcare is that US GLP-1 NET PRICING has collapsed by government design while VOLUME has been unlocked - a volume-for-price trade. TrumpRx (Tier 1, US government) now sells Zepbound at $299/mo from a $1,087 list, and Medicare covers obesity drugs for the first time at a ~$50/mo copay. That asymmetry rewards whoever takes enough share to more than offset price. Lilly is the only company owning BOTH the injectable incumbent (Zepbound/Mounjaro) AND the oral disruptor (Foundayo/orforglipron, FDA-approved 2026-04-01), with retatrutide behind it - and the TRIUMPH Phase 3 read out on 2026-07-23 at up to -20.8% body weight. MFN price compression transfers share TO Lilly rather than away from it. 2026 revenue $85.35B (+30.95%), EPS $34.62 (+43.01%); 2027 revenue $98.74B (+15.69%), EPS $44.87 (+29.59%). July PT raises: Citi $1,500->$1,600, Bernstein $1,300->$1,385, UBS $1,250->$1,425. | at 33.5x forward with a consensus PT implying only ~+6%, the sell side sees the story as fully priced - the weakest valuation support of any name on this upside list; MFN/TrumpRx is structurally deflationary even for the winner; Novo sued Lilly on 2026-07-21 and sought a preliminary injunction on 07-24 to block Lilly's DTC advertising - a live legal risk to its key launch channel | 78 |
| AEM | Essentially unlevered equity on the gold price, with the best margin structure and balance sheet in this research. Gold at ~$4,124 on the run date (+21.4% YoY) against a largely fixed cost base is direct margin expansion - and unlike oil, gold's drivers here (geopolitical instability PLUS an inflationary oil shock) are reinforced rather than undermined by the Iran situation. D/E of 0.01 means shareholders capture the full operating leverage with essentially no financial risk: 39.46% profit margin, 7.31x EV/EBITDA, 11.62x forward earnings, $4.54B TTM FCF, total debt $319M against $3.12B cash. Hold ratings fell 6 -> 4 over six months. | a durable US-Iran settlement removes the geopolitical bid - reports of Pakistan/China mediation already knocked crude ~3% on 07-24; a September rate hike raises real yields, gold's primary headwind; FY27 EPS growth decelerates sharply to +5.67% - the easy comps end, and the analyst PT range ($87-$300) is extraordinarily wide, signalling low conviction on the gold deck | 76 |
| NOC | The defense cycle is intact and the trade has inverted: money moved out of narrative (PLTR -20.5%, TDG -22.6%, AXON -28.8%, LDOS -31.6%, AVAV -45.2% over 52 weeks) and into appropriated backlog (HWM +55.2%, LMT +38.9%, RTX +36.0%, GD +22.0%). NOC is the ONLY large prime down over 52 weeks (-4.62%) - and it beat and raised on 07-21, one day before the run date: EPS $7.68 vs $6.82, FY26 EPS guidance raised to $28.60-29.10 from $27.40-27.90, a record $105B backlog and $20B of net awards (~1.9x quarterly book-to-bill). The FY2027 budget request (released 2026-04-03) is $1.5T total defense, +24% real discretionary, weighted to hardware, with ~$55B for a Defense Autonomous Warfare Group where NOC has the deepest franchise among primes. EV/EBITDA has compressed from 21.38 in FY2023 to 14.92. | THE UNRESOLVED QUESTION: six firms cut price targets IMMEDIATELY AFTER the beat-and-raise (Susquehanna $785->$655, Baird $700->$500, DB $645->$615, JPM $635->$600, TD Cowen $580->$550), and only UBS raised. B-21 initial LRIP lots are fixed-price - historically NOC's charge mechanism - and current charge status is UNVERIFIED. This is the single most important unresolved item in the defense work and the reason the estimate-revisions subscore is capped at 68.; Sentinel ICBM cost/schedule breach risk; the FY27 budget is a REQUEST, not law - discretionary spending needs 60 Senate votes | 74 |
▼ Downside skew — 1yrconviction
| Ticker | Thesis | Key risk | Score |
|---|---|---|---|
| ARM | Grows revenue ~21-23% and trades at ~120x forward earnings - a PEG above 5 - with EV/EBITDA at 238.99. The structural problem the AI cycle does not fix: royalty revenue scales with UNITS, not with silicon value, and units are falling (smartphones -12.9%, PCs -11.3%, per IDC). This is the clearest negative revision cluster in the semiconductor complex: HSBC downgraded to Hold from Buy on 2026-07-14 citing foundry capacity constraints limiting earnings growth; UBS cut $470->$360 on 07-20 (-23%); Wells Fargo cut $410->$350 on 07-22, the run date itself (-15%). Only Susquehanna raised. FY2027 consensus: revenue $5.97B (+21.3%), EPS $2.17 (+22.5%), 37 analysts. | datacentre CPU attach (Grace/Graviton/Axion) could inflect royalty RATES rather than units; any AI-licensing announcement re-rates it instantly; SoftBank ownership concentration makes the float squeezable - this is the real hazard in shorting it; earnings 2026-07-29, INSIDE the catalyst horizon | 81 |
| NVO | Triple structural price compression on the same molecule, all three confirmed. (a) TrumpRx MFN pricing: Ozempic $199/mo from $1,028, Wegovy Pen $199 from $1,349 (Tier 1, trumprx.gov). (b) IRA Round 2: Ozempic AND Wegovy negotiated at -44% net, effective 2027-01-01 - i.e. INSIDE the 12-month window. (c) Competitive share loss: Lilly's orforglipron launched 2026-04-01 and retatrutide read out 2026-07-23. Novo eats the price cut without the offsetting share. The tell is mechanical: forward P/E (16.00) is HIGHER than trailing (11.48) - the market is explicitly modelling earnings decline. 2026 consensus revenue DKK 293.81B (-4.94%), EPS 20.97 (-8.93%), 28 analysts, and the consensus PT sits BELOW the market price. Guidance was cut 2026-02-04 citing pricing pressure, patent expirations and competition; CagriSema missed and requires a new study. Behavioural tell: Novo sued Lilly on 2026-07-21 and sought a preliminary injunction on 07-24 to block a competitor's advertising - not the posture of a company winning on product. | semaglutide has real volume upside from Medicare's first-ever obesity coverage at a ~$50/mo copay; 9.1x EV/EBITDA on a 37.2% net margin is genuinely cheap - this is a crowded, already-repriced short; HSBC raised its target to DKK 300 on 07-21; Q2 earnings 2026-08-05, same day as LLY | 79 |
| TSLA | Volumes are recovering while economics collapse. The Q2 print released AMC on the run date itself: revenue $28.236B BEAT consensus $26.4B and deliveries grew 25% YoY to 480,126 - but non-GAAP EPS was $0.33 against ~$0.51 consensus, operating margin 1.4%, operating income -57% to $398M, and free cash flow -$1.092B with capex +142% to $5.8B. Tesla has converted from an auto manufacturer earning 15%+ operating margins into a capex-heavy AI/robotics R&D vehicle funded by a barely-profitable car business. At ~162x forward earnings with negative FCF, essentially the entire market cap is the robotaxi/Optimus option - and management offered limited new concrete milestones on either on the call. | a credible, dated, revenue-generating robotaxi rollout at scale - the option is real, not fictional; deliveries are GROWING 25%, not shrinking: the post-credit-expiry demand cliff bears expected did not materialise; net cash of ~$27B means no financing risk and no forced-deleveraging catalyst - this can stay expensive indefinitely; data conflict: Q2 deliveries reported as 480,126 (Electrek) vs 489,126 (Teslarati), unreconciled | 78 |
| QCOM | The ONLY large cap in the entire semiconductor universe screened with declining consensus revenue AND declining EPS. FY2026 consensus: revenue $42.58B (-3.86% YoY), EPS $10.81 (-10.14% YoY), 31 analysts. Three independent structural pressures compound at once: losing its largest socket to Apple modem in-sourcing, paying more for inputs (memory crunch - it signed long-term automotive memory supply agreements with Micron ~07-17, which is sensible AND confirms where the pricing power sits), and selling into a shrinking unit market (smartphone units -12.9%, IDC). UBS cut $235->$190 around 07-21. INFERENCE, FLAGGED AS MINE: a 16.94 forward P/E at $166.97 implies forward-year EPS of ~$9.86 - BELOW the FY2026 estimate of $10.81 - meaning consensus appears to model two consecutive down years. This is my arithmetic from the aggregator's own figures; the FY2027 consensus itself was paywalled. | 16.9x with $12.5B of FCF and ~32% consensus upside is not an expensive short; auto/IoT diversification is real and growing; already ~36% below its 52-week high, so much of the modem cliff is priced; FQ3 earnings 2026-07-29, INSIDE the catalyst horizon | 76 |
| MRNA | The cleanest negative asymmetry in this research on the numbers. The stock is +87.5% over 52 weeks while revenue FELL 30% to $2.23B TTM, gross margin is NEGATIVE (-69.9%), operating margin is -113.9%, TTM FCF is -$1.60B and EPS is -$8.16. Consensus PT of $45.85 sits ~44% BELOW spot, rated Hold by 24 analysts. Equity eroded from $13.85B to $7.41B while debt went from ~zero to $1.25B. Management reorganised into three franchises explicitly preparing for launches in 2027 and 2028 - the company itself does not expect 2026 to be the revenue trough. RUNWAY (my arithmetic from two sourced figures, flagged as inference): net cash ~$3.96B against -$1.60B annual FCF implies roughly 2-2.5 years; company runway guidance is UNVERIFIED. | A NEAR-TERM BINARY SITS DIRECTLY ON TOP OF THE RUN-UP: the mRNA-1010 flu vaccine PDUFA is 2026-08-05 and the adcomm voted 9-0 in favour on 2026-06-18. An approval is a real, dated, high-probability-looking catalyst against this short.; Merck-partnered intismeran autogene cut melanoma recurrence/death risk 49% at 5 years (2026-06-01); Q2 earnings 2026-07-31 | 76 |
| DE | A peak-quality multiple on trough-and-still-falling fundamentals: 31.65x forward earnings on a third consecutive year of revenue decline. Revenue $61.25B (FY23) -> $51.72B (FY24) -> $45.68B (FY25); net income $10.17B -> $7.10B -> $5.03B; operating margin 25.26% -> 24.27% -> 20.64%. That is -25% revenue and -51% net income since FY2023. FY26E revenue $41.5B (-9.15%), FY26E EPS $18.06 (-2.36%). THE STRUCTURAL POINT IS TIER-1 AND UNDERAPPRECIATED: USDA ERS forecasts 2026 net farm income of $153.4B (-2.6% inflation-adjusted), and the support is TRANSFER PAYMENTS, not demand - government payments +45.2% to $44.3B, 'primarily due to higher anticipated payments from Farm Bill programs that trigger payments when commodity prices fall', while crop cash receipts rise only +1.2% (a decline in real terms). Farmers receiving deficiency payments do not buy $800,000 combines; equipment capex tracks crop receipts, not total farm income. Quality-of-earnings flag: Q2 FY26 margins were partly boosted by a $272M one-time tariff refund. Citi raised its PT to $610 on 07-13 but kept Neutral - and $610 is BELOW the market price. | the trough-buying argument is live and has mainstream backing (Barron's, 2026-07-09: 'Farming Is Terrible Right Now. That's Good for Deere and AGCO Stocks'); the 2026-06-12 White House ag-equipment tariff cut is a direct cost tailwind; FY2027/28 estimates are being revised UPWARD, implying the street already treats FY2026 as the trough; precision-ag software and the dealer network are genuine moats | 73 |
| NET | The single most unsupportable large-cap multiple found in this research: ~202x forward earnings for 31.6% revenue growth, unprofitable (EPS -0.25), with the stock near its 52-week high AND a consensus price target of $259.84 that sits BELOW the current price. It is the only name in the entire cross-desk dataset where the sell side has marked its target under spot while the stock sits near its high - complete capitulation on upside with no valuation cushion. The broader structural point: the market spent 2026 punishing app-layer SaaS on terminal-value fear while data/infra/security names saw market caps rise 31-99% on 20-31% growth at 80-200x forward with GAAP losses. That cohort - NET, CRWD (140x fwd), SNOW (127x fwd), DDOG (100x fwd), PANW (82.5x fwd on EPS -34.1%) - is where the crowding, and therefore the unpriced downside, actually sits. In a probable-hike regime these are the highest-duration assets in software. | Cloudflare's edge/inference positioning is genuinely strategic and could see an AI-workload inflection that resets the growth rate upward; shorting momentum at a 52-week high is how people lose money; no debt distress; this is a MULTIPLE short, not a fundamental one - revenue is compounding at 31.6% | 72 |
| SLB | The cleanest structural short in energy because it loses in BOTH states of the world. The central paradox of mid-2026: crude is up ~38% YoY while SLB's earnings estimates are FALLING. Its book is international/offshore-weighted and concentrated in exactly the Middle East geographies now disrupted by the Iran conflict and Hormuz throttling - war raises the oil price but halts the drilling SLB is paid for (Saudi output already fell 7,010 -> 6,637 kbpd May->June 2026). Then, if the conflict resolves, prices fall toward EIA's $65 Brent 2027 case and operators cut budgets. FY2026 EPS $2.53, revised DOWN 13.73% from $2.93. FY2027 consensus assumes a +30.15% EPS rebound to $3.29 - an aggressive recovery resting on the same de-escalation that E&P bulls fear. THE TWO CONSENSUS VIEWS ARE MUTUALLY INCONSISTENT, and that inconsistency is the thesis. Corroborated intraday by Track A: HAL fell 5.47% on a double beat on 07-21 specifically on Middle East revenue -10.7%. | a durable peace could unleash pent-up Middle East reconstruction spend; FY27 consensus already assumes recovery, so a beat re-rates fast; consensus is still Buy with ~17% PT upside - this is a contrarian position; data flag: shown EV/EBITDA of 4.52 is irreconcilable with a 25.42 trailing P/E - flagged UNVERIFIED and not used; FCF listed as n/a | 72 |
| INFY | The purest expression of AI disrupting the labour-arbitrage pyramid, and one of very few names in software/services with genuinely FALLING forward estimates. Trailing P/E 13.17 vs forward P/E 13.26 - forward ABOVE trailing, the mechanical signal of negative revisions. Revenue TTM $20.30B, +4.1%: the weakest growth of any name examined across five research desks. Consensus rating Hold, only 14 analysts, PT implying ~+6.7% - by far the weakest analyst support in the dataset. The mechanism: services revenue is billable hours x headcount, precisely what agentic AI compresses. The sector repriced violently on 2026-06-18 when Accenture cut guidance from 3-5% to 3-4% local-currency growth, missed on revenue and posted bookings -2%; ACN fell ~18%, its worst single-day drop on record, with Capgemini -8.4%, CTSH -5.8%, INFY -3.2%. | THERE IS A REAL HOLE IN THE CONSENSUS STORY: Accenture's HEADCOUNT ROSE during the quarter it missed, CTSH's bookings rose 21%, and IBM tripled entry-level hiring despite claiming developers are 40% more productive. Revenue deceleration is documented; the causal attribution to AI is NOT.; at ~13x with ADR/FX effects, much is priced; if AI INTEGRATION demand materialises, services firms capture it; related names ACN (10.25x fwd, 4.44% yield) and CTSH (7.86x fwd, FCF +31.6%) are explicitly NOT recommended as shorts - too cheap; express as underweight | 70 |
| HWM | SHORT THE MULTIPLE, NOT THE BUSINESS - and the low composite reflects exactly that. The most extreme multiple expansion found anywhere in this research: forward P/E 24.29 (FY21) -> 26.72 (FY23) -> 36.19 (FY24) -> 48.99 (FY25) -> 54.80 now; EV/EBITDA 16.69 -> 45.56, a 173% expansion in five years; P/S 2.70 -> 13.42. A reversion to even the FY2025 EV/EBITDA of 36.35x is roughly a 20% drawdown with NO change to earnings. Consensus PT implies only ~+7.75% even at a Strong Buy rating. Q2 guidance ($2.39-2.41B revenue, $1.22-1.24 EPS, reporting 08-06) is a narrow band with little beat room. In a probable-hike regime, 45x EV/EBITDA is the most rate-sensitive kind of asset there is. | THIS IS NOT A FUNDAMENTAL SHORT AND THE ESTIMATE-REVISIONS SUBSCORE OF 40 SAYS SO EXPLICITLY: estimates are RISING. FY26E revenue $9.76B (+18.24%), EPS $5.06 (+34.31%); the company RAISED FY26 EPS guidance to $4.88-5.00 from $4.35-4.55; Jefferies, TD Cowen, Morgan Stanley, Citi and UBS all raised targets; consensus is Strong Buy.; genuine oligopoly in investment-cast turbine airfoils; the hyperscaler/industrial-gas-turbine demand leg is a new, uncorrelated vector the market may still be underwriting; 737 rate increases are direct volume | 60 |
C · Options Heat
Where the premium is paying up
| Ticker | Signal | Read | Implication | Lag |
|---|---|---|---|---|
| INTC | iv_spike | weekly IV 175 -> 200 across 07-21/07-22 vs a 52-week IV range of 38-102; Aug 105-129; weekly straddle 105 = ~13% expected move; call/put 1.8:1 easing to 1.5:1 into the print | bullish-skewed, but overwhelmingly event premium into 07-23 AMC earnings. Weekly IV at roughly 2x the top of its own annual range means the buyer of premium needs a >13% move to win. IV-crush risk is the dominant post-event exposure. | Market Rebellion intraday/pre-market snapshots, NOT exchange settlement. No contract-level volume-vs-prior-OI available on any free source for a historical date - a true vol/OI ratio was NOT computable for any name in this run. |
| NOW | iv_spike | weekly IV 160 -> 193 vs 52-week range 28-76; Aug 105-110; straddle 102 = ~12% expected move; call/put FLIPPED from 1:1.2 to 2.6:1 into the print | direction flipped decisively bullish late into a 07-22 AMC report; large move priced. The flip itself is the signal - positioning changed hands inside 24 hours. | Intraday snapshots, not settlement. Directional inference from chain skew, not from confirmed order flow. |
| TXN | pc_skew | call/put 11.5:1, concentrated in Aug 350 calls; weekly IV 128 -> 156 vs 52-week range 24-71 | strongly bullish-skewed with unusual single-strike concentration. Single-strike concentration is more consistent with a deliberate structure than with diffuse retail buying. | Intraday snapshot. Cannot distinguish opening from closing interest without vol/OI, which is unavailable free. |
| GOOGL | iv_spike | weekly IV 73 -> 81 -> 94 across 07-20/07-21/07-22 vs 52-week range 25-44; Aug 66; call/put decayed 4:1 -> 1.9:1 | bullish positioning DECAYING into the 07-22 AMC print - the crowd was reducing directional conviction while IV rose. In hindsight consistent with the capex-raise reaction. | Intraday snapshots across three sessions; directionally sound, absolute levels will not match end-of-day chains. |
| TSLA | iv_spike | weekly IV 94 vs 52-week range 39-65 (~45% above the range top); Aug 60; call/put 1.4:1 | uncertain - event premium dominates. The options market priced a large move without a clear side into the 07-22 AMC report. | Intraday snapshot, not settlement. |
| NVDA | sweep | ~$63.2M total block premium on 07-22 - $63.1M call-side against $102K of put-side selling. The largest single-name print of the session. | bullish. Institutional-scale premium in the AI-complex bellwether on a day the sector sold off - accumulation into weakness rather than chase. | SetYourStop third-party block aggregation. This is NOT a consolidated sweep tape; buy/sell-side attribution is INFERRED from print location, not exchange-confirmed. Read 'call buying' as 'call-side premium'. |
| AVGO | sweep | ~$22.7M block premium, $22.6M call-side | bullish; corroborates the NVDA print as a broader AI-semis accumulation footprint rather than a single-name view. | Same inferred-attribution caveat; no consolidated tape. |
| MU | sweep | ~$12.7M net block premium but composed of ~$15.8M PUT SELLING plus $3.1M call selling | bullish-to-neutral - this is premium COLLECTION into elevated IV, not directional call buying. A materially weaker bullish signal than the headline premium number suggests, and the reason MU's options subscore is 74 rather than 90. | Inferred attribution. Distinguishing opening from closing interest is impossible without vol/OI. |
| SNDK | sweep | $40.4M call-side premium against $33.0M put-side premium - net only +$7.4M on very large two-way gross | uncertain / hedged. The near-symmetric gross is the informative part: real two-way business around a violent move, which argues against a pure retail-chase reading despite the mention spike. | Inferred attribution, no consolidated tape. |
| SMCI | iv_spike | ~$10.5M block premium ($9M call-side); option-chain IV 107; call/put 3.4:1 | bullish, and a component of the PUMP_RISK flag - heavy call-side premium on a vertical move whose primary source could not be retrieved. | Inferred attribution; IV from an intraday chain snapshot. |
| DELL | pc_skew | $11.6M block premium (bullish-leaning) against an option chain skewed PUT-heavy at 1:1.2, IV 84 | mixed - flow and chain skew disagree. Someone was positioned against the +9.32% sympathy rally. Reported as genuinely ambiguous rather than resolved in either direction. | Inferred block attribution; chain snapshot is intraday. |
| SPCX | sweep | three prints on 07-22: 129-strike calls 30DTE $868K; 180-strike calls 240DTE $988K; and 330-strike calls with NINE DAYS TO EXPIRY for $748K against a spot of $115.26 - roughly 186% out of the money | speculative bullish - the 9DTE 330-strike is a pure lottery structure, not a hedge or a position. Highest pump-risk profile in the window. See pump_risk_watch. | Inferred attribution. Float, short interest and market cap could NOT be verified on free sources, so universe eligibility is unconfirmed - this name is reported as an options/sentiment observation, not ranked in either track. |
| CBOE_EQUITY_PC | pc_skew | UNVERIFIED - DO NOT QUOTE A LEVEL. Two sources disagree by ~3x on the same nominal series: Convex publishes 07-20 1.47, 07-21 1.25, 07-22 1.60, 07-23 1.95; YCharts' CBOE Equity Put/Call Ratio shows 0.55 with data ENDING 2026-07-10. A 1.25-1.95 reading is impossible for the CBOE equity P/C, which historically runs 0.4-0.9, so the Convex series is either mislabelled, an index P/C, or a proprietary construction. | No name-level or market-level P/C conclusion is drawn in this run. The one directional observation offered without an absolute level: the Convex series rose 07-21 -> 07-22 and spiked further on 07-23. THE BRIEF'S PRIORITY-3 SIGNAL IS ESSENTIALLY UNAVAILABLE FOR THIS DATE. | Authoritative free source (YCharts) has no data past 2026-07-10. Unresolved rather than reconciled, because reconciling would require guessing which series Convex actually publishes. |
| VIX_COMPLEX | iv_spike | VIX fell through the window: 18.65 (07-20) -> 17.05 (07-21) -> 16.64 (07-22) DESPITE a heavy earnings slate. Term structure in contango (VIX1D 10.14 / VIX9D 15.48 / spot 17.05 / VIX3M 19.59 / front future 18.45). SKEW elevated at 151.66. COR3M 7.99, DSPX 47.51. VXN at a 56% premium to VIX; OVX 63.78 (~4x VIX). | Index-level complacency with paid-up tail protection - cheap at-the-money vol alongside expensive OTM downside puts. Implied correlation in single digits with dispersion near its range top confirms a single-name-driven, index-suppressed earnings regime, which is exactly what the Track A dispersion shows. Oil vol was the cross-asset outlier. Convex separately flagged a VIX-credit divergence z-score of +1.9 as of 07-21 (equity vol complacent versus credit) - their own backtest claim, INDEPENDENTLY UNVERIFIED. | Saxo brief published 07-22 reports the 07-21 close - a one-day publication offset, reconciled against the Convex VIXCLS daily series. Anyone reusing these figures must apply the same correction. |
D · Catalyst Calendar
Upcoming events
| Date | Event | Tickers | IV move |
|---|---|---|---|
| 2026-07-23 | Q2 2026 earnings (AMC) - Tier-1 confirmed via Intel IR | INTC | high |
| 2026-07-23 | Q2 2026 earnings (BMO) - broad cross-sector day | TMUSTMOLMTRTXUNPHONCMCSAFCXNSCDLRBX | unknown |
| 2026-07-23 | Q2 2026 earnings (AMC) | EWSAM | unknown |
| 2026-07-23 | European large-cap Q2 results; US-listed ADRs trade the reaction | SAPTTE | unknown |
| 2026-07-24 | Q2 2026 earnings (BMO) | VZAXPCHTRSLBHCANEECNILWBAH | unknown |
| 2026-07-27 | Durable Goods Orders (June), 08:30 ET | MACRO | normal |
| 2026-07-27 | Q2 2026 earnings (BMO) - Tier-2 confirmed | AZN | unknown |
| 2026-07-27 | Q2 2026 earnings - day placement UNVERIFIED (single aggregator source) | BKRNUEAPLDWHR | unknown |
| 2026-07-28 | FOMC meeting DAY 1 (no decision); plus Conference Board Consumer Confidence (July), Case-Shiller Home Price Index (May), trade balance and inventories (June) | MACRO | normal |
| 2026-07-28 | Q2 2026 earnings - BA/V/UPS/PYPL Tier-1 IR-confirmed; KO moderate confidence; F/STX/ENPH/RCL day placement UNVERIFIED | BAVUPSPYPLKOFSTXENPHRCL | unknown |
| 2026-07-29 | FOMC INTEREST RATE DECISION 14:00 ET + Fed Chair Warsh press conference 14:30 ET. Target range entering: 3.50-3.75%. Tier-1 confirmed on federalreserve.gov. | MACRO | high |
| 2026-07-29 | FY26 Q4 earnings (AMC) - Tier-1 confirmed via Microsoft IR | MSFT | unknown |
| 2026-07-29 | Q2 2026 earnings (AMC) - Tier-1 confirmed via Meta IR | META | unknown |
| 2026-07-29 | FQ3 2026 earnings (AMC) - Tier-2 confirmed | QCOM | unknown |
| 2026-07-29 | FQ1 FY2027 earnings - Tier-2 confirmed | ARM | unknown |
| 2026-07-29 | Q4 FY26 / Q2 2026 earnings - PG Tier-1 confirmed; SBUX/BSX/ADP day placement UNVERIFIED | PGSBUXBSXADP | unknown |
E · Trade Ideas
What the data implies
INTCneutral · track A
Rationale This is a VOLATILITY observation, not a directional call. Weekly IV at ~200 against a 52-week IV range of 38-102 means the options market was pricing a ~13% move into the 07-23 AMC print - roughly double the top of its own annual vol range. When premium is that rich, the buyer needs to be right about magnitude AND direction; the seller only needs the move to be smaller than priced. The call/put skew easing from 1.8:1 to 1.5:1 into the print says directional conviction was FADING even as premium rose.
Invalidation n/a for the vol view. For anyone expressing it directionally: a close back below the 07-20 pre-rally level would negate the momentum leg.
Risk Intel is a policy-adjacent, narrative-driven name where gap risk exceeds what the chain prices. IV data is an intraday snapshot, not settlement. Direction is genuinely uncertain - I am not expressing one.
SMCIneutral · track A
Rationale Ranked #2 on momentum but carrying an explicit PUMP_RISK flag, which makes 'long' indefensible and 'short' reckless. The +19.84% rests on a SELF-REPORTED, UNAUDITED ~$60B backlog whose primary press release could not be retrieved (ir.supermicro.com 404s), paired with SOFT revenue guidance in the same release, in a low-priced high-retail-attention name where the sell side moved in opposite directions the same week (Mizuho to $34, Needham to $46).
Invalidation For a long: failure to confirm the $60B backlog in the formal filing, or a close back below the 07-21 pre-announcement level (~$25.50 area, derived from the $30.56 close less the 19.84% move). For a short: independent confirmation of the backlog and the 15-17% gross-margin guide.
Risk PUMP_RISK: TRUE. The single most important missing datapoint in this run is SMCI's own press release. Do not size this on secondary summaries.
MUlong · track A
Rationale The strongest credibility-weighted Track A signal: top-2 mention counts on BOTH r/wallstreetbets and StockTwits (i.e. real sentiment velocity) combined with a genuine Tier-1-quoted sell-side catalyst rather than pure crowd noise - BofA's Arya raising to $1,550 on an 8th consecutive beat with HBM TAM to $246B by 2030, and UBS modelling >40% share repurchase and >$400B FCF through 2028. Momentum, sentiment and a fundamental anchor line up. ↔ in deep-dive library.
Invalidation DRAM contract pricing turning outright negative QoQ, or customer inventories breaching the 8-week warning line (they were at 7-9 weeks); mechanically, a close back below the 07-20 pre-rally level.
Risk THE TWO TRACKS DISAGREE ON THIS NAME AND THAT IS THE POINT. MU ranks #3 on Track A and appears on NEITHER Track B list, because Track B research classifies memory as LATE-CYCLE: DRAM contract pricing decelerating +90-95% -> +58-63% -> +13-18% QoQ, customer inventories at 7-9 weeks, and Micron guiding to an 86% gross margin roughly 25 points above the 2018 peak. A 6.4x forward P/E on peak-cycle earnings is not cheap. Consensus peak timing has migrated to Q3-Q4 2027. Trade the momentum if you want; do not confuse it with a 12-month thesis.
GEVneutral · track A
Rationale The cleanest 'beat-and-sold-off' instance of the window: revenue beat, FY guidance RAISED, and the stock fell 8.69% on a Q2 EPS miss ($2.47 vs $3.04-3.13) after an ~80% H1 run. Options had pre-positioned for size without a side (weekly IV 113-114 vs a 52-week range of 40-72, call/put ~1:1) and were right about magnitude. The structural story is genuinely strong (orders +88% YoY on a $176B backlog); the multiple is the problem at ~41x FY27E.
Invalidation For a long: a second consecutive quarter of wind-segment margin drag, or a close below the 07-22 low. For a short: order book acceleration reasserting itself, which the backlog data currently supports.
Risk GEV is simultaneously one of the strongest structural stories in the power complex and a legitimate de-rating candidate on multiple. Those are not contradictory - they resolve on the discount rate, which is what 07-29 is about.
TSMlong · track B
Rationale The highest-conviction 12-month idea in this run (composite 90). ~31% forward-year revenue growth at 19.05x forward earnings with $79.70B of net cash, in a regime that has begun punishing capex spenders and de-rating high-multiple AI derivatives. TSM monetises the buildout regardless of whether merchant GPUs or custom ASICs win - every other semiconductor name in this research is its customer. Verified forward years: 2027 revenue NT$7.05T (+30.9%), EPS NT$136.05 (+27.9%). July PT raises from Barclays and TD Cowen.
Invalidation THESIS INVALIDATION: leading-edge or CoWoS capacity ceasing to be the binding constraint (i.e. supply catching demand), or a hyperscaler digestion phase showing up in TSMC's own monthly revenue prints. NOT invalidated by multiple compression alone - the discount is geopolitical.
Risk TAIWAN GEOPOLITICAL TAIL RISK IS UNHEDGEABLE AND IS THE ENTIRE REASON THIS TRADES AT 19x. Anyone underwriting this thesis is underwriting that risk explicitly, not incidentally. Position size should reflect a non-zero probability of permanent capital loss, which is not true of the other names on this list.
VSTlong · track B
Rationale The widest gap in the research between an intact fundamental story and a compressed multiple. Order evidence across the power complex is the strongest of the cycle (GEV orders +88%/$176B backlog; ETN Electrical backlog +29% with 1.1 book-to-bill; PWR $48.5B) while merchant IPPs sit 20-33% below 52-week highs. At 17.44x forward, 10.79x EV/EBITDA and a 0.38 PEG, VST is where that dislocation is widest. All six Jun-Jul analyst actions maintained Buy; Wells Fargo moved $152 -> $259.
Invalidation THE THESIS IS EXPLICITLY A DISCOUNT-RATE CALL, so it is invalidated by rates rather than by demand: a hawkish 07-29 FOMC or a confirmed September hike path directly worsens a D/E of 3.55 on $19.93B of debt. Fundamentally, invalidation is a book-to-bill slipping below 1.0 across the power complex, or ERCOT/PJM spark spreads compressing on a mild weather year.
Risk The most rate-exposed name on the Track B upside list, entering a week with an FOMC decision inside the catalyst horizon. Merchant power spreads are unhedged commodity exposure - a mild weather year IS an earnings miss regardless of the AI-power narrative. Source statistics page is cached 2026-05-29; multiples are approximate.
NVOshort · track B
Rationale Triple structural price compression on the same molecule, ALL THREE CONFIRMED FROM PRIMARY OR NEAR-PRIMARY SOURCES: TrumpRx MFN pricing (Ozempic $199/mo from $1,028; Wegovy $199 from $1,349 - Tier 1, trumprx.gov); IRA Round 2 negotiating both drugs at -44% net effective 2027-01-01, which lands INSIDE the 12-month window; and competitive share loss to Lilly's orforglipron and retatrutide. The mechanical tell is that forward P/E (16.00) exceeds trailing (11.48) - the market is explicitly modelling earnings decline - and consensus PT sits BELOW the market price. Novo suing Lilly over advertising on 07-21 and seeking an injunction on 07-24 is a behavioural tell, not a business strategy.
Invalidation Medicare's first-ever obesity coverage at a ~$50/mo copay driving volume growth that MORE than offsets the -44% net price - i.e. the volume-for-price trade working in Novo's favour rather than Lilly's. Concretely: any quarter where semaglutide script volume growth exceeds the net-price decline. Also invalidated if oral Wegovy takes meaningful retail share.
Risk THIS IS A CROWDED SHORT AND IT IS GENUINELY CHEAP - 9.1x EV/EBITDA on a 37.2% net margin, with a 2.64% dividend. Being right on the direction and wrong on the entry is the main way to lose here. Q2 earnings 08-05, same day as LLY, is a two-sided event.
SLBshort · track B
Rationale Loses in BOTH oil regimes, which is rare enough to be worth stating plainly. War raises the crude price but halts the international/offshore drilling SLB is paid for (Saudi output 7,010 -> 6,637 kbpd May->June 2026); peace lowers the price toward the EIA's $65 Brent 2027 case and operators cut budgets. FY2026 EPS has been revised DOWN 13.73% to $2.53 while crude is up ~38% YoY - the paradox IS the thesis. FY2027 consensus assumes a +30.15% EPS rebound that requires the same de-escalation E&P bulls fear; the two consensus views are mutually inconsistent. Track A corroborates intraday: HAL fell 5.47% on a DOUBLE BEAT on 07-21, specifically on Middle East revenue -10.7%.
Invalidation A durable US-Iran settlement that unleashes pent-up Middle East reconstruction and drilling spend - i.e. the FY27 consensus recovery actually arriving. Watch international rig counts and Saudi/Iraq/Kuwait activity, not the crude price. A single quarter of international revenue re-accelerating breaks this.
Risk Consensus is still BUY with ~17% PT upside - this is explicitly a contrarian position against the sell side. Source data conflict: the aggregator's EV/EBITDA of 4.52 is irreconcilable with a 25.42 trailing P/E and was NOT used. SLB reports 07-24, inside the catalyst horizon.
MSFTlong · track B
Rationale A SELLER of the agentic tools disrupting the rest of software, at 20.61x forward - the cheapest in years - roughly 31% below its high with FY26E revenue growth ACCELERATING to +17.0% and EPS +23.0%. 42 Strong Buy / 13 Buy / 3 Hold of 58 covering analysts. Unlike app-layer SaaS it sits on the correct side of the seat-pricing question. ↔ in deep-dive library.
Invalidation THE 07-29 CAPEX GUIDE IS THE INVALIDATION EVENT AND IT IS INSIDE THIS RUN'S CATALYST HORIZON. Alphabet beat every line on the run date and the market focused entirely on its raised capex; MSFT is not exempt. A capex guide that materially compresses FCF, or Azure growth decelerating, breaks the thesis. Note also that sources conflict on MSFT's own 2026 capex - $120B+ vs ~$190B - and that is UNVERIFIED.
Risk Two large uncorrelated events land within hours of each other on 07-29: the FOMC decision at 14:00 ET and MSFT earnings AMC. This is the single most event-dense day for this position in the horizon.
ARMshort · track B
Rationale ~120x forward earnings and 238.99x EV/EBITDA for 21-23% growth - a PEG above 5 - against a structural problem the AI cycle does not fix: royalty revenue scales with UNITS, and units are falling (smartphones -12.9%, PCs -11.3%, IDC). The clearest negative revision cluster in the semiconductor complex: HSBC downgraded to Hold on 07-14 citing foundry capacity constraints, UBS cut $470->$360 on 07-20, Wells Fargo cut $410->$350 on 07-22 - the run date itself. Only Susquehanna raised.
Invalidation Datacentre CPU attach (Grace/Graviton/Axion) inflecting royalty RATES rather than units - the one path that breaks the units-based bear case. Any AI-licensing announcement re-rates this instantly.
Risk SOFTBANK OWNERSHIP CONCENTRATION MAKES THE FLOAT SQUEEZABLE - this is the highest-variance short in the run, and earnings land 07-29, INSIDE the catalyst horizon. A 120x multiple can become 180x before it becomes 40x. Unlimited-risk expressions are inappropriate here.
ISRGshort · track A
Rationale The smallest move on the Track A falling list (-2.68%) and the most durable information in it. The FDA granted marketing authorization to J&J's Ottava - the first credible US rival to da Vinci in soft-tissue robotics. That is a Tier-1 regulatory fact that permanently changes a competitive position rather than a quarterly datapoint, which is why the catalyst subscore (92) far exceeds the momentum subscore (52). The market moved 2.68% on a change to a monopoly. Already reported down ~35% YTD into this.
Invalidation Ottava's commercial rollout proving slow, surgeon-training-constrained or clinically inferior - installed-base and switching costs in surgical robotics are formidable and da Vinci's lead is measured in years, not quarters. Evidence would be J&J placement counts materially undershooting.
Risk A 2.68% move is not a signal on its own; this idea rests entirely on the DURABILITY of the catalyst, not its magnitude. If Ottava stumbles, the thesis simply evaporates with no offsetting support. ISRG did not appear on the Track B downside list precisely because the fundamental case was not developed to that standard.
Methodology & limitations
- BACKDATED RUN. Compiled 2026-07-26 for a 2026-07-22 run date. Post-run-date PRICE REACTIONS (07-23, 07-24) were deliberately excluded from all scoring to avoid look-ahead contamination. Track B valuation multiples and market caps nonetheless carry a 07-24 to 07-26 vintage because free aggregators serve current snapshots only - every affected name is marked post_run_date_vintage. Track A moves, closes and catalysts are strictly in-window.
- NO CONTRACT-LEVEL VOLUME-VS-PRIOR-OI IS AVAILABLE ON ANY FREE SOURCE FOR A HISTORICAL DATE. The brief's PRIORITY-1 options signal was therefore NOT computable for any name in this run. Premium concentration was substituted, which is a materially weaker proxy - it cannot distinguish opening from closing interest.
- NO CONSOLIDATED SWEEP/BLOCK TAPE. All 'call buying' figures come from a third-party aggregation (SetYourStop) where buy/sell-side attribution is INFERRED from print location, not exchange-confirmed. Read every such figure as 'call-side premium', not confirmed directional buying.
- PUT/CALL RATIO IS UNRESOLVED AND NO LEVEL IS QUOTED. Two sources disagree by ~3x on the same nominal series and the authoritative one (YCharts CBOE Equity P/C) has no data past 2026-07-10. The brief's priority-3 signal is essentially unavailable for this date.
- ALL IV FIGURES ARE INTRADAY OR PRE-MARKET SNAPSHOTS (Market Rebellion), not exchange settlement values. Cross-session comparisons are directionally sound; absolute levels will not match end-of-day chains. No formal IV rank or IV percentile was obtainable - 52-week IV RANGES were used instead.
- SENTIMENT TRACKERS HAVE NO HISTORICAL MODE ON FREE TIERS. ApeWisdom, tradestie and both AltIndex dashboards are live. Snapshots used are dated 07-23 to 07-25. In-window peaks are INFERRED from large negative 24h deltas (MU -35%, TSLA -60%, SPCX -54%, INTC -67%) - real evidence, but inference rather than measurement. Every mention count should be read as post-window with a higher inferred in-window peak.
- BARCHART FREE UOA, MARKET CHAMELEON FREE AND THE BENZINGA UOA CALENDAR - all named in the brief - serve current-session snapshots only with no historical date parameter. Everything date-specific came from published daily articles that happen to be crawlable, not from the screeners the brief specifies.
- r/SecurityAnalysis AND r/options PRODUCED NOTHING RETRIEVABLE for this window. Tier-1 sentiment leans on one Substack plus sell-side quoted secondhand, which is thinner than the brief's methodology intends. The Reddit scope is therefore only partially satisfied.
- MARKET CAPS ARE AGGREGATOR FIGURES AS OF ~07-24 TO 07-26, NOT AS OF THE EVENT DATE. This matters only for names near the threshold: ZION ($10.16B, borderline, excluded from the ranked list), HAS ($12.36B), HUT ($12.38B), IREN ($13.25B). RKLB's aggregator cap is stale. DELL's cap is derived rather than directly sourced.
- FY2027 CONSENSUS IS PAYWALLED FOR MANY TICKERS on free sources. Explicit forward-year figures were obtained for TSM, LLY, MRK, AZN, ARM, QCOM (partially), SLB and others; for VST, NVDA, MSFT, NOC and several more, 'estimate revisions' is INFERRED from price-target revision direction and current-year growth rather than an observed estimate series. Subscores are capped accordingly. True estimate-revision history (dollar revisions over time) is unavailable on any free source at any price point.
- NO TIER-1 SEC VERIFICATION WAS PERFORMED FOR ANY VALUATION FIGURE. All multiples are Tier-2 aggregator data (stockanalysis.com, sourcing S&P Global Market Intelligence / TipRanks).
- SEVERAL MAJOR OUTLETS ARE FETCH-BLOCKED (CNBC, Seeking Alpha, Smartkarma, Globe and Mail, US News return 403 or block via robots.txt). Headlines corroborate ticker sets but body figures were unretrievable, which is why several Track A names carry close_unverified flags.
- SMCI'S PRIMARY PRESS RELEASE WAS NOT RETRIEVABLE (ir.supermicro.com returns 404). The ~$60B backlog figure - the entire basis of the #2-ranked rising name - rests on secondary summaries. This is the single most important unverified datapoint in the run.
- NOC: SIX FIRMS CUT PRICE TARGETS IMMEDIATELY AFTER A BEAT-AND-RAISE and the reason was not established. B-21 fixed-price LRIP charge status is UNVERIFIED. This is the largest unresolved question behind a Track B upside ranking.
- MERCK'S KEYTRUDA QLEX SUBCUTANEOUS CONVERSION RATE is not disclosed and is the single most important number for that thesis - UNVERIFIED.
- SECTORS REQUESTED BUT NOT COVERED IN TRACK B, stated so absence is not read as a signal: regional banks with CRE exposure (zero data - the largest hole), office/CRE fundamentals, Chinese EV ADRs (NIO, XPEV, LI), RIVN and LCID. PAYX was not researched, which is a material gap in the ADP thesis.
- NO FDA PDUFA, INVESTOR-DAY, INDEX-REBALANCE OR LOCKUP-EXPIRY PASS was run for the catalyst horizon. Their absence from the calendar is a coverage gap, not a verified absence.
- SCORES ARE HEURISTIC AND NOT BACKTESTED. Sub-signals that could not be verified are set to a neutral 50 and flagged, never guessed. Composites are fully reconstructable from the published weights and sub-scores.
- TRACK A IS HEAVILY CONCENTRATED: 7 of 10 rising names are one correlated factor (the AI-server/memory/storage complex that repriced on 07-21). This is an accurate description of the window, not a diversified list.
- NOTE ON A KNOWN FORWARD RISK, DISCLOSED FOR CALIBRATION RATHER THAN USED IN SCORING: the memory-complex rally in this window reversed sharply within two sessions. Any reader treating the Track A rising list as durable should weigh that the signal's half-life in this regime was short.
Not financial advice. Educational/analytical only — generated by Daily Market Pulse template v1 - backdated run for 2026-07-22, compiled 2026-07-26 via five parallel research desks (market regime, Track A movers, options+sentiment, catalyst calendar, Track B fundamentals). Do your own diligence.